Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115855 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Antonio da Silva Menezes Junior und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina, Departamento de Clínica Médica, Universidade Federal de Goiás (UFG), Goiânia 74020-020, Brazil. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Oxidation-Reduction, Mutation, Signal Transduction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by cellular and metabolic dysfunction, with mitochondrial dysfunction playing a crucial role. Although the direct relationship between genetic mutations and mitochondrial dysfunction remains unclear, targeting mitochondrial dysfunction presents promising opportunities for treatment, as there are currently no effective treatments available for HCM. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews guidelines. Searches were conducted in databases such as PubMed, Embase, and Scopus up to September 2023 using “MESH terms”. Bibliographic references from pertinent articles were also included. Hypertrophic cardiomyopathy (HCM) is influenced by ionic homeostasis, cardiac tissue remodeling, metabolic balance, genetic mutations, reactive oxygen species regulation, and mitochondrial dysfunction. The latter is a common factor regardless of the cause and is linked to intracellular calcium handling, energetic and oxidative stress, and HCM-induced hypertrophy. Hypertrophic cardiomyopathy treatments focus on symptom management and complication prevention. Targeted therapeutic approaches, such as improving mitochondrial bioenergetics, are being explored. This includes coenzyme Q and elamipretide therapies and metabolic strategies like therapeutic ketosis. Understanding the biomolecular, genetic, and mitochondrial mechanisms underlying HCM is crucial for developing new therapeutic modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Medicina, Departamento de Clínica Médica, Universidade Federal de Goiás (UFG), Goiânia 74020-020, Brazil.
- Faculdade de Medicina, Universidade de Rio Verde (UniRV), Campus Aparecida, Aparecida de Goiânia 74345-030, Brazil.
ORCID-Profile: Antonio da Silva Menezes Junior, Ana Luísa Guedes de França-E-Silva, Iane de Oliveira Pires Porto, Thays Millena Alves Pedroso, Aguinaldo F Freitas
Zitieren
APA
Menezes Junior, A. D. S., França-E-Silva, A. L. G., Oliveira, H. L., Lima, K. B. A., Porto, I. O. P., Pedroso, T. M. A., Silva, D. M. E., & Freitas, A. F. (2024). Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115855
Vancouver
Menezes Junior ADS, França-E-Silva ALG, Oliveira HL, Lima KBA, Porto IOP, Pedroso TMA, et al. Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115855
BibTeX
@article{MenezesJunior2024,
author = {Menezes Junior, Antonio da Silva and França-E-Silva, Ana Luísa Guedes de and Oliveira, Henrique Lima de and Lima, Khissya Beatryz Alves de and Porto, Iane de Oliveira Pires and Pedroso, Thays Millena Alves and Silva, Daniela de Melo E and Freitas, Aguinaldo F},
title = {Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115855}
}
EUVIMED